Cue Biopharma (CUE) vs NervGen Pharma (NGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Cue Biopharma (CUE) has outperformed NervGen Pharma (NGEN) over the past year, losing 0.4% versus a loss of 48.0%. Over five years, NGEN leads with a -8.5% price change compared with -92.7% for CUE. Cue Biopharma is the larger company by market cap ($200.9 million vs $186.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CUE | NGEN |
|---|---|---|
| Share price | $27.66 | $1.73 |
| Market cap | $200.93M | $186.01M |
| 1-day change | +23.87% | -1.14% |
| YTD return | +202.30% | -69.11% |
| 1-year return | -0.43% | -48.05% |
| 5-year return | -92.68% | -8.47% |
| EPS (TTM) | $-29.59 | $-0.57 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $45.50 | $6.30 |
| 52-week low | $4.98 | $1.58 |
| Distance from 52-week high | -39.21% | -72.54% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +218.15% | +478.03% |
| Average volume | 268.82K | 557.47K |
| Shares outstanding | 7.26M | 107.52M |
| Employees | 29 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CUE has outperformed NGEN by 47.6 percentage points over the past year.
About Cue Biopharma
CUE stock →Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 29 employees
About NervGen Pharma
NGEN stock →NervGen Pharma Corp., a biotechnology company, engages in the discovery, development, and commercialization of pharmaceutical treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), stroke, multiple sclerosis, and Alzheimer's disease; and NVG-300, which is in a preclinical model of ischemic stroke, amyotrophic lateral sclerosis, and confirmatory SCI study.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
CUE vs NGEN FAQ
Which is bigger, Cue Biopharma or NervGen Pharma?
Cue Biopharma (CUE) is larger, with a market capitalization of $200.93M compared with $186.01M for NervGen Pharma (NGEN).
Which stock has performed better over the past year, CUE or NGEN?
CUE returned -0.43% over the past 12 months, compared with -48.05% for NGEN (price return, excluding dividends). Past performance does not predict future results.
Are Cue Biopharma and NervGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.